1887

Abstract

Influenza B viruses fall in two antigenically distinct lineages (B/Victoria/2/1987 and B/Yamagata/16/1988 lineage) that co-circulate with influenza A viruses of the H3N2 and H1N1 subtypes during seasonal epidemics. Infections with influenza B viruses contribute considerably to morbidity and mortality in the human population. Influenza B virus neutralizing antibodies, elicited by natural infections or vaccination, poorly cross-react with viruses of the opposing influenza B lineage. Therefore, there is an increased interest in identifying other correlates of protection which could aid the development of broadly protective vaccines. analysis revealed high sequence identity of all viral proteins. With two online epitope prediction algorithms, putative conserved epitopes relevant for study subjects used in the present study were predicted. The cross-reactivity of influenza B virus-specific polyclonal CD8 cytotoxic T-lymphocyte (CTL) populations obtained from HLA-typed healthy study subjects, with intra-lineage drift variants and viruses of the opposing lineage, was determined by assessing their IFN-γ response and lytic activity. Here, we show for the first time, to the best of our knowledge, that CTLs directed to viruses of the B/Victoria/2/1987 lineage cross-react with viruses of the B/Yamagata/16/1988 lineage and vice versa.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000156
2015-08-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/8/2061.html?itemId=/content/journal/jgv/10.1099/vir.0.000156&mimeType=html&fmt=ahah

References

  1. Altenburg A.F. , Kreijtz J.H. , de Vries R.D. , Song F. , Fux R. , Rimmelzwaan G.F. , Sutter G. , Volz A. . ( 2014;). Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6: 2735–2761 [CrossRef] [PubMed].
    [Google Scholar]
  2. Ambrose C.S. , Levin M.J. . ( 2012;). The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8: 81–88 [CrossRef] [PubMed].
    [Google Scholar]
  3. Antrobus R.D. , Berthoud T.K. , Mullarkey C.E. , Hoschler K. , Coughlan L. , Zambon M. , Hill A.V. , Gilbert S.C. . ( 2014;). Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 22: 233–238 [CrossRef] [PubMed].
    [Google Scholar]
  4. Assarsson E. , Bui H.H. , Sidney J. , Zhang Q. , Glenn J. , Oseroff C. , Mbawuike I.N. , Alexander J. , Newman M.J. . ( 2008;). Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 82: 12241–12251 [CrossRef] [PubMed].
    [Google Scholar]
  5. Belshe R.B. . ( 2010;). The need for quadrivalent vaccine against seasonal influenza. Vaccine 28: (Suppl 4), D45–D53 [CrossRef] [PubMed].
    [Google Scholar]
  6. Belshe R.B. , Coelingh K. , Ambrose C.S. , Woo J.C. , Wu X. . ( 2010;). Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28: 2149–2156 [CrossRef] [PubMed].
    [Google Scholar]
  7. Beran J. , Wertzova V. , Honegr K. , Kaliskova E. , Havlickova M. , Havlik J. , Jirincova H. , Van Belle P. , Jain V. . ( 2009;). Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 9: 2 [CrossRef] [PubMed].
    [Google Scholar]
  8. Berthoud T.K. , Hamill M. , Lillie P.J. , Hwenda L. , Collins K.A. , Ewer K.J. , Milicic A. , Poyntz H.C. , Lambe T. . ( 2011;). Potent CD8+T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1–7 [CrossRef] [PubMed].
    [Google Scholar]
  9. Bodewes R. , Morick D. , deMutsert G. , Osinga N. , Bestebroer T. , vanderVliet S. , Smits S.L. , Kuiken T. , Rimmelzwaan G.F. . ( 2013;). Recurring influenza B virus infections in seals. Emerg Infect Dis 19: 511–512 [CrossRef] [PubMed].
    [Google Scholar]
  10. Boon A.C. , de Mutsert G. , Graus Y.M. , Fouchier R.A. , Sintnicolaas K. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2002;). The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol 76: 582–590 [CrossRef] [PubMed].
    [Google Scholar]
  11. Boon A.C. , De Mutsert G. , Fouchier R.A. , Sintnicolaas K. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2004;). Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 172: 4435–4443 [CrossRef] [PubMed].
    [Google Scholar]
  12. Boyce W.M. , Sandrock C. , Kreuder-Johnson C. , Kelly T. , Cardona C. . ( 2009;). Avian influenza viruses in wild birds: a moving target. Comp Immunol Microbiol Infect Dis 32: 275–286 [CrossRef] [PubMed].
    [Google Scholar]
  13. CDC ( 2009;). Update: influenza activity – United States, September 28, 2008–April 4, 2009, and composition of the 2009–10 influenza vaccine. MMWR Morb Mortal Wkly Rep 58: 369–374 [PubMed].
    [Google Scholar]
  14. CDC ( 2013;). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices United States, 2013–2014. MMWR Recomm Rep 62: (RR-07),1–43 [PubMed].
    [Google Scholar]
  15. CDC ( 2014;). Past weekly surveillance reports. http://www.cdc.gov/flu/weekly/pastreports.htm.
  16. Chen R. , Holmes E.C. . ( 2008;). The evolutionary dynamics of human influenza B virus. J Mol Evol 66: 655–663 [CrossRef] [PubMed].
    [Google Scholar]
  17. Chen J.M. , Guo Y.J. , Wu K.Y. , Guo J.F. , Wang M. , Dong J. , Zhang Y. , Li Z. , Shu Y.L. . ( 2007;). Exploration of the emergence of the Victoria lineage of influenza B virus. Arch Virol 152: 415–422 [CrossRef] [PubMed].
    [Google Scholar]
  18. Daemen T. , de Mare A. , Bungener L. , de Jonge J. , Huckriede A. , Wilschut J. . ( 2005;). Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 57: 451–463 [CrossRef] [PubMed].
    [Google Scholar]
  19. Darriba D. , Taboada G.L. , Doallo R. , Posada D. . ( 2012;). jModelTest 2: more models, new heuristics and parallel computing. Nat Methods 9: 772 [CrossRef] [PubMed].
    [Google Scholar]
  20. Domachowske J.B. , Pankow-Culot H. , Bautista M. , Feng Y. , Claeys C. , Peeters M. , Innis B.L. , Jain V. . ( 2013;). A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis 207: 1878–1887 [CrossRef] [PubMed].
    [Google Scholar]
  21. Dreyfus C. , Laursen N.S. , Kwaks T. , Zuijdgeest D. , Khayat R. , Ekiert D.C. , Lee J.H. , Metlagel Z. , Bujny M.V. . ( 2012;). Highly conserved protective epitopes on influenza B viruses. Science 337: 1343–1348.[CrossRef]
    [Google Scholar]
  22. Epstein S.L. . ( 2006;). Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49–53 [CrossRef] [PubMed].
    [Google Scholar]
  23. FDA ( 2012;). FDA News Release: FDA approves first quadrivalent vaccine to prevent seasonal influenza. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm.
  24. Feng L. , Shay D.K. , Jiang Y. , Zhou H. , Chen X. , Zheng Y. , Jiang L. , Zhang Q. , Lin H. . ( 2012;). Influenza-associated mortality in temperate and subtropical Chinese cities, 2003–2008. Bull World Health Organ 90: 279–288B [CrossRef] [PubMed].
    [Google Scholar]
  25. Fiore A.E. , Uyeki T.M. , Broder K. , Finelli L. , Euler G.L. , Singleton J.A. , Iskander J.K. , Wortley P.M. , Shay D.K. . ( 2010;). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59: (RR-8), 1–62 [PubMed].
    [Google Scholar]
  26. Flynn K.J. , Belz G.T. , Altman J.D. , Ahmed R. , Woodland D.L. , Doherty P.C. . ( 1998;). Virus-specific CD8+T cells in primary and secondary influenza pneumonia. Immunity 8: 683–691 [CrossRef] [PubMed].
    [Google Scholar]
  27. Gao R. , Cao B. , Hu Y. , Feng Z. , Wang D. , Hu W. , Chen J. , Jie Z. , Qiu H. . ( 2013;). Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368: 1888–1897 [CrossRef] [PubMed].
    [Google Scholar]
  28. Guindon S. , Gascuel O. . ( 2003;). A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696–704 [CrossRef] [PubMed].
    [Google Scholar]
  29. Guindon S. , Dufayard J.F. , Lefort V. , Anisimova M. , Hordijk W. , Gascuel O. . ( 2010;). New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307–321 [CrossRef] [PubMed].
    [Google Scholar]
  30. Hall T.A. . ( 1999;). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41: 95–98.
    [Google Scholar]
  31. He X.S. , Holmes T.H. , Zhang C. , Mahmood K. , Kemble G.W. , Lewis D.B. , Dekker C.L. , Greenberg H.B. , Arvin A.M. . ( 2006;). Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80: 11756–11766 [CrossRef] [PubMed].
    [Google Scholar]
  32. Heikkinen T. , Ikonen N. , Ziegler T. . ( 2014;). Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis 59: 1519–1524.[CrossRef]
    [Google Scholar]
  33. Heinonen S. , Silvennoinen H. , Lehtinen P. , Vainionpää R. , Ziegler T. , Heikkinen T. . ( 2011;). Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 11: 23–29 [CrossRef] [PubMed].
    [Google Scholar]
  34. Hillaire M.L. , van Trierum S.E. , Kreijtz J.H. , Bodewes R. , Geelhoed-Mieras M.M. , Nieuwkoop N.J. , Fouchier R.A. , Kuiken T. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2011;). Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 92: 2339–2349 [CrossRef] [PubMed].
    [Google Scholar]
  35. Hillaire M.L. , Vogelzang-van Trierum S.E. , Kreijtz J.H. , de Mutsert G. , Fouchier R.A. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2013;). Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. J Gen Virol 94: 583–592 [CrossRef] [PubMed].
    [Google Scholar]
  36. Hoft D.F. , Babusis E. , Worku S. , Spencer C.T. , Lottenbach K. , Truscott S.M. , Abate G. , Sakala I.G. , Edwards K.M. . ( 2011;). Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204: 845–853 [CrossRef] [PubMed].
    [Google Scholar]
  37. Jameson J. , Cruz J. , Ennis F.A. . ( 1998;). Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 72: 8682–8689 [PubMed].
    [Google Scholar]
  38. Jameson J. , Cruz J. , Terajima M. , Ennis F.A. . ( 1999;). Human CD8+ and CD4+T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162: 7578–7583 [PubMed].
    [Google Scholar]
  39. Kieninger D. , Sheldon E. , Lin W.Y. , Yu C.J. , Bayas J.M. , Gabor J.J. , Esen M. , Fernandez Roure J.L. , Narejos Perez S. . ( 2013;). Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥ 18 years. BMC Infect Dis 13: 343 [CrossRef] [PubMed].
    [Google Scholar]
  40. Kimura M. . ( 1981;). Estimation of evolutionary distances between homologous nucleotide sequences. Proc Natl Acad Sci U S A 78: 454–458 [CrossRef] [PubMed].
    [Google Scholar]
  41. Koel B.F. , Burke D.F. , Bestebroer T.M. , van der Vliet S. , Zondag G.C. , Vervaet G. , Skepner E. , Lewis N.S. , Spronken M.I. . ( 2013;). Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342: 976–979.[CrossRef]
    [Google Scholar]
  42. Kreijtz J.H. , Bodewes R. , van Amerongen G. , Kuiken T. , Fouchier R.A. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2007;). Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612–620 [CrossRef] [PubMed].
    [Google Scholar]
  43. Kreijtz J.H. , de Mutsert G. , van Baalen C.A. , Fouchier R.A. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2008;). Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161–5166 [CrossRef] [PubMed].
    [Google Scholar]
  44. Kreijtz J.H. , Bodewes R. , van den Brand J.M. , de Mutsert G. , Baas C. , van Amerongen G. , Fouchier R.A. , Osterhaus A.D. , Rimmelzwaan G.F. . ( 2009;). Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27: 4983–4989 [CrossRef] [PubMed].
    [Google Scholar]
  45. Langley J.M. , Carmona Martinez A. , Chatterjee A. , Halperin S.A. , McNeil S. , Reisinger K.S. , Aggarwal N. , Huang L.M. , Peng C.T. . ( 2013;). Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 208: 544–553 [CrossRef] [PubMed].
    [Google Scholar]
  46. Lee L.Y. , Ha L.A. , Simmons C. , de Jong M.D. , Chau N.V. , Schumacher R. , Peng Y.C. , McMichael A.J. , Farrar J.J. . ( 2008;). Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478–3490 [PubMed].
    [Google Scholar]
  47. Lindstrom S.E. , Hiromoto Y. , Nishimura H. , Saito T. , Nerome R. , Nerome K. . ( 1999;). Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. J Virol 73: 4413–4426 [PubMed].
    [Google Scholar]
  48. Lundegaard C. , Nielsen M. , Lund O. . ( 2006;). The validity of predicted T-cell epitopes. Trends Biotechnol 24: 537–538 [CrossRef] [PubMed].
    [Google Scholar]
  49. McCullers J.A. , Saito T. , Iverson A.R. . ( 2004;). Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 78: 12817–12828 [CrossRef] [PubMed].
    [Google Scholar]
  50. McMichael A.J. , Gotch F.M. , Noble G.R. , Beare P.A. . ( 1983;). Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13–17 [CrossRef] [PubMed].
    [Google Scholar]
  51. O'Neill E. , Krauss S.L. , Riberdy J.M. , Webster R.G. , Woodland D.L. . ( 2000;). Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81: 2689–2696 [PubMed].[CrossRef]
    [Google Scholar]
  52. Olson D.R. , Heffernan R.T. , Paladini M. , Konty K. , Weiss D. , Mostashari F. . ( 2007;). Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med 4: e247 [CrossRef] [PubMed].
    [Google Scholar]
  53. Paiva T.M. , Benega M.A. , Silva D.B. , Santos K.C. , Cruz A.S. , Hortenci M.F. , Barbieri M.T. , Monteiro M.M. , Barbosa H.A. , Carvalhanas T.R. . ( 2013;). Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996–2012: implications for vaccine composition strategy. J Med Virol 85: 1983–1989 [CrossRef] [PubMed].
    [Google Scholar]
  54. Pérez-Girón J.V. , Belicha-Villanueva A. , Hassan E. , Gómez-Medina S. , Cruz J.L. , Lüdtke A. , Ruibal P. , Albrecht R.A. , García-Sastre A. , Muñoz-Fontela C. . ( 2014;). Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J Immunol 193: 1324–1332 [CrossRef] [PubMed].
    [Google Scholar]
  55. Quinones-Parra S. , Grant E. , Loh L. , Nguyen T.H. , Campbell K.A. , Tong S.Y. , Miller A. , Doherty P.C. , Vijaykrishna D. . ( 2014;). Preexisting CD8+T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci U S A 111: 1049–1054.[CrossRef]
    [Google Scholar]
  56. Rimmelzwaan G.F. , Baars M. , Claas E.C. , Osterhaus A.D. . ( 1998;). Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro . J Virol Methods 74: 57–66 [CrossRef] [PubMed].
    [Google Scholar]
  57. Rimmelzwaan G.F. , Nieuwkoop N. , Brandenburg A. , Sutter G. , Beyer W.E. , Maher D. , Bates J. , Osterhaus A.D. . ( 2000;). A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19: 1180–1187 [CrossRef] [PubMed].
    [Google Scholar]
  58. Rimmelzwaan G.F. , deJong J.C. , Bartelds A.I. , Wilbrink B. , Fouchier R.A. , Osterhaus A.D. . ( 2003;). [The 2001/2002 influenza season and the vaccine composition for the 2002/ season]. Ned Tijdschr Geneeskd 146: 1846–1850 (in Dutch).
    [Google Scholar]
  59. Robbins P.A. , Lettice L.A. , Rota P. , Santos-Aguado J. , Rothbard J. , McMichael A.J. , Strominger J.L. . ( 1989;). Comparison between two peptide epitopes presented to cytotoxic T lymphocytes by HLA-A2.Evidence for discrete locations within HLA-A2. J Immunol 143: 4098–4103 [PubMed].
    [Google Scholar]
  60. Robbins P.A. , Garboczi D.N. , Strominger J.L. . ( 1995;). HLA-A*0201 complexes with two 10-Mer peptides differing at the P2 anchor residue have distinct refolding kinetics. J Immunol 154: 703–709 [PubMed].
    [Google Scholar]
  61. Robbins P.A. , Rota P.A. , Shapiro S.Z. . ( 1997;). A broad cytotoxic T lymphocyte response to influenza type B virus presented by multiple HLA molecules. Int Immunol 9: 815–823 [CrossRef] [PubMed].
    [Google Scholar]
  62. Roider J. , Meissner T. , Kraut F. , Vollbrecht T. , Stirner R. , Bogner J.R. , Draenert R. . ( 2014;). Comparison of experimental fine-mapping to in silico prediction results of HIV-1 epitopes reveals ongoing need for mapping experiments. Immunology 143: 193–201 [CrossRef] [PubMed].
    [Google Scholar]
  63. Rota P.A. , Wallis T.R. , Harmon M.W. , Rota J.S. , Kendal A.P. , Nerome K. . ( 1990;). Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175: 59–68 [CrossRef] [PubMed].
    [Google Scholar]
  64. Rota P.A. , Hemphill M.L. , Whistler T. , Regnery H.L. , Kendal A.P. . ( 1992;). Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 73: 2737–2742 [CrossRef] [PubMed].
    [Google Scholar]
  65. Russell C.A. , Jones T.C. , Barr I.G. , Cox N.J. , Garten R.J. , Gregory V. , Gust I.D. , Hampson A.W. , Hay A.J. . ( 2008;). Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26: (Suppl 4), D31–D34 [CrossRef] [PubMed].
    [Google Scholar]
  66. Shaw M.W. , Xu X. , Li Y. , Normand S. , Ueki R.T. , Kunimoto G.Y. , Hall H. , Klimov A. , Cox N.J. , Subbarao K. . ( 2002;). Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000–2001 and 2001–2002 seasons. Virology 303: 1–8 [CrossRef] [PubMed].
    [Google Scholar]
  67. Silver M.L. , Parker K.C. , Wiley D.C. . ( 1991;). Reconstitution by MHC-restricted peptides of HLA-A2 heavy chain with beta 2-microglobulin, in vitro . Nature 350: 619–622 [CrossRef] [PubMed].
    [Google Scholar]
  68. Simonsen L. , Clarke M.J. , Williamson G.D. , Stroup D.F. , Arden N.H. , Schonberger L.B. . ( 1997;). The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 87: 1944–1950 [CrossRef] [PubMed].
    [Google Scholar]
  69. Slepushkin A.N. . ( 1959;). The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull World Health Organ 20: 297–301 [PubMed].
    [Google Scholar]
  70. Smith D.J. , Lapedes A.S. , de Jong J.C. , Bestebroer T.M. , Rimmelzwaan G.F. , Osterhaus A.D. , Fouchier R.A. . ( 2004;). Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371–376.[CrossRef]
    [Google Scholar]
  71. Sridhar S. , Begom S. , Bermingham A. , Hoschler K. , Adamson W. , Carman W. , Bean T. , Barclay W. , Deeks J.J. , Lalvani A. . ( 2013;). Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19: 1305–1312 [CrossRef] [PubMed].
    [Google Scholar]
  72. Thompson W.W. , Shay D.K. , Weintraub E. , Brammer L. , Cox N. , Anderson L.J. , Fukuda K. . ( 2003;). Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179–186 [CrossRef] [PubMed].
    [Google Scholar]
  73. Thompson W.W. , Shay D.K. , Weintraub E. , Brammer L. , Bridges C.B. , Cox N.J. , Fukuda K. . ( 2004;). Influenza-associated hospitalizations in the United States. JAMA 292: 1333–1340 [CrossRef] [PubMed].
    [Google Scholar]
  74. Tinoco J.C. , Pavia-Ruz N. , Cruz-Valdez A. , Aranza Doniz C. , Chandrasekaran V. , Dewé W. , Liu A. , Innis B.L. , Jain V.K. . ( 2014;). Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥ 18 years: a phase III, randomized trial. Vaccine 32: 1480–1487 [CrossRef] [PubMed].
    [Google Scholar]
  75. Ulmer J.B. . ( 2002;). Influenza DNA vaccines. Vaccine 20: (Suppl 2), S74–S76 [CrossRef] [PubMed].
    [Google Scholar]
  76. van de Sandt C.E. , Kreijtz J.H. , Rimmelzwaan G.F. . ( 2012;). Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 4: 1438–1476 [CrossRef] [PubMed].
    [Google Scholar]
  77. van de Sandt C.E. , Kreijtz J.H. , de Mutsert G. , Geelhoed-Mieras M.M. , Hillaire M.L. , Vogelzang-van Trierum S.E. , Osterhaus A.D. , Fouchier R.A. , Rimmelzwaan G.F. . ( 2014a;). Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol 88: 1684–1693 [CrossRef] [PubMed].
    [Google Scholar]
  78. van de Sandt C.E. , Kreijtz J.H. , Geelhoed-Mieras M.M. , Vogelzang-van Trierum S.E. , Nieuwkoop N.J. , van de Vijver D.A. , Fouchier R.A. , Osterhaus A.D. , Morein B. , Rimmelzwaan G.F. . ( 2014b;). Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine 32: 5614–5623 [CrossRef] [PubMed].
    [Google Scholar]
  79. van der Burg S.H. , Visseren M.J. , Brandt R.M. , Kast W.M. , Melief C.J. . ( 1996;). Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156: 3308–3314 [PubMed].
    [Google Scholar]
  80. Weinfurter J.T. , Brunner K. , Capuano S.V. III , Li C. , Broman K.W. , Kawaoka Y. , Friedrich T.C. . ( 2011;). Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 7: e1002381 [CrossRef] [PubMed].
    [Google Scholar]
  81. Westgeest K.B. , de Graaf M. , Fourment M. , Bestebroer T.M. , van Beek R. , Spronken M.I. , de Jong J.C. , Rimmelzwaan G.F. , Russell C.A. . ( 2012;). Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J Gen Virol 93: 1996–2007 [CrossRef] [PubMed].
    [Google Scholar]
  82. WHO ( 2014a;). WHO Recommendations on the Composition of Influenza Virus Vaccines. http://www.who.int/influenza/vaccines/virus/recommendations/en.
  83. WHO ( 2014b;). Influenza (Seasonal) Fact Sheet 211. http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
  84. Yewdell J.W. , Bennink J.R. , Smith G.L. , Moss B. . ( 1985;). Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785–1789 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000156
Loading
/content/journal/jgv/10.1099/vir.0.000156
Loading

Data & Media loading...

Supplementary Data



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error